Thus, it seems important in PV and ET, which are JAK2-dependent MPNs, to obtain specific inhibitors of JAK2V617F or even to preferentially target the constitutive active JAK2 over cytokine-activated JAK2 in the cases of mutatedMPL andCALR ET and MF. The gene discussed is JAK2; the disease is essential thrombocythemia.